High dose IGF-1 therapy

Details High dose IGF-1 therapy High dose IGF-1 therapy

1996-03-01

1999-09-07

Tsang, Cecilia J.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514 3, 530303, A61K 3800, A61K 3828

Patent

active

059487577

ABSTRACT:
The present invention involves a method for providing high dose IGF-I therapy by administering a complex of IGF-I and IGFBP-3. The IGF-I/IGFBP-3 complex may be given at unexpectedly high doses without inducing IGF-I-related side effects.

REFERENCES:
patent: 5126324 (1992-06-01), Clark et al.
patent: 5187151 (1993-02-01), Clark et al.
patent: 5202119 (1993-04-01), Clark et al.
Malozowski et al. (1994) "Risks and Benefits of Insulin-like Growth Factor," Ann. Internal Med. 121(7):549.
Cioffi et al. (1994) "Insulin-Like Growth Factor-1 Lowers Protein Oxidation in Patients with Thermal Injury," Annals of Surgery 220(3):310-319.
Takano et al. (1990) "Effects of sc Administration of Recombinant Human Insulin-Like Growth Factor I (IGF-I) on Normal Human Subjects," Endocrinol. Japon. 37(2):309-317.
Klinger et al. (1993) "Acute Effects of IGF-1 in Patients with Laron Syndrome and Normal Subjects," Pediatr. Adolesc. Endocrinol. 24:221-225.
Ebling et al. (1995) "Short-Term Effects of Recombinant Human Insulin-Like Growth Factor I on Bone Turnover in Normal Women," J. Clin. Endocrinol. Metabolism 77(5):1384-1387.
Miller et al. (1994) "Effects of IGF-I on Renal Function in End-Stage Chronic Renal Failure," Kidney International 46:201-207.
Thompson et al. (1995) "The Effects of Recombinant Human Insulin-Like Growth Factor-I and Growth Hormone on Body Composition in Ederly Women," J. Clin. Endocrinol. Metabolism 80(6):1845-1852.
Lieberman et al. (1994) "Anabolic Effects of Recombinant Insulin-Like Growth Factor-I in Cachectic Patients with the Acquired Immunodeficiency Syndrome," J. Clin. Endocrinol. 78(2):404-410.
Laron et al. (1991) "Biochemical and Hormonal Changes Induced by One Week of Administration of rIGF-I to Patients with Laron Type Dwarfism," Clin. Endocrinol. 35:145-150.
Grinspoon et al. (1995) "Effects of rhIGF-I Administration on Bone Turnover During Short-Term Fasting," The American Society of Clinical Investigation, Inc. 96:900-906.
Guler et al.(1987) "Short-Term Metabolic Effects of Recombinant Human Insulin-Like Growth Factor I In Healthy Adults," New England J. Medicine 317:137-140.
Jabri et al. (1994) "Adverse Effects of Recombinant Human Insulin-Like Growth Factor I in Obese Insulin-Resistant Type II Diabetic Patients," Diabetes 43:369-274.
Stong et al. (1993) "Effects of Multiple Subcutaneous Doses of rhIGF-1 on Total and Free IGF-1 Levels and Blood Glucose in Humans," Ann. New York Acad. Sci. 692:317-320.
Adams, S., et al., "Protection from hypoglycemic response to IGF-I by administration of IGF-I with its binding protein IGFBP-3 in the rat and monkey" The Endocrine Society, 77th Annual Meeting, Jun. 14-17, 1995, Washington, D.C., p. 186.
Blum et al., "Plasma IGFBP-3 levels as clinical indicators" Modern Concepts in Insulin-Like Growth Factors, (1991) E.M. Spencer, ed., Elsevier, New York, pp. 381-393.
Zapf et al., "Intravenously injected insulin-like growth factor (IGF) I/IGF binding protein-3 complex exerts insulin-like effects in hypophysectomized, but not in normal rats" Clinical Investigation (1994) 95:179-186.
Baxter, "Circulating levels and molecular distribution of the acid-labile (.alpha.) subunit of the high molecular weight insulin-like growth factor-binding protein complex" J. Clin. Endocrinol. (1990) 70:1347-1353.
Rinderknecht et al., "Polypeptides with nonsuppressible insulin-like and cell-growth promoting activities in human serum: Isolation, chemical characterization, and some biological properties of forms I and II" Proc. Natl. Acad. Sci. USA (1976) 73:2365-2369.
Baxter et al., "Growth hormone-dependent insulin-like growth factors (IGF) binding protein from human plasma differs from other human IGF binding proteins" Biochem. Biophys. Res. Comm. (1986) 139:1256-1261.
Sommer et al., "Molecular genetics and actions of recombinant insulin-like growth factor binding protein-3" Modern Concepts of Insulin-Like Growth Factors (1991) E.M. Spencer, ed., Elsevier, New York, pp. 715-728.
Clemmons et al., "Uses of human insulin-like growth factor-1 in clinical conditions" J. Clin. Endocrinol. Metabol. (1994) 79:4-6.
Clark et al., "Insulin-like growth factor I stimulation of lymphopoiesis" J. Clin. Invest. (1993) 92:540-548.
Delany et al., "Cellular and clinical perspectives on skeletal insulin-like growth factor I" J. Cell. Biochem. (1994) 55:328-333.
Steenfos, "Growth factors and wound heeling" Scand. J. Plast. Reconstr. Surg. Hand Surg. (1994) 28:95-105.
Lewis et al., "Insulin-like growth factor I: Potential for treatment of motor neuronal disorders" Exp. Neurol. (1993) 124:73-88.
Lieberman et al., "Effects of recombinant human insulin-like growth factor-I (rhIGF-I) on total and free IGF-I concentrations, IGF-binding proteins and glycemic response in humans" J. Clin. Endocrinol. Metab. (1992) 75:30-36.
Guler et al., "Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults" New Engl. J. Med. (1987) 317:137-140.
Goth, "Drug absorption and distribution" Medical Pharmacology 13th edition, (1992) Clark, W. G. et al., eds., Mosby Year Book, St. Louis, pp. 33-34.
Goodman et al., The Pharmacological Basis of Therapeutics, Eighth edition, (1990) Gilman et al., eds., Pergamon Press, New York. The title page and table of contents are included herewith.
Baxter et al., "Structure of the M.sub.r 140,000 growth hormone-dependent insulin-like growth factor binding protein complex: Determination by reconstitution and affinity-labeling" Proc. Natl. Acad. Sci. USA (1989) 86:6898-6902.
Baxter et al., "Regulation of the insulin-like growth factors and their binding proteins by glucocorticoid and growth hormone in nonislet cell tumor hypoglycemia" J. Clin. Endocrinol. Metabol. (1995) 80:2700-2708.
Baxter et al., "Purification and characterization of the acid-labile subunit of rat serum insulin-like growth factor binding complex" Endocrinol. (1994) 134:848-852.
Davies et al., "Physiological parameters in laboratory animals and humans " Pharm. Res. (1993) 10:1093-1095.
Bagi et al., "Benefit of systemically administered rhIGF-I and rhIGF-I/IGFBP-3 on cancellous bone in ovariectomzed rats" J. Bone Mineral Res. (1994) 9:1301-1311.
Bagi et al., "Systemic administration of rhIGF-I or rhIGF-I/IGFBP-3 increases cortical bone and lean body mass in ovariectomized rats" bone (1995) 16:263S-269S.
Bagi et al., "Treatment of ovariectomized rats with the complex of rh1GF/IGFBP-3 increases cortical and cancellous bone mass and improve structure in the femoral neck" Calcif. Tissue Int. (1995) 57:40-46.
Bengtsson et al., "Treatment of adults with growth hormone (GH) deficiency with recombinant human GH" J. Clin. Endocrinol. (1993) 76:309-317.
Ross et al., "Critically ill patients have high basal growth hormone levels with attenuated oscillatory activity associated with low levels of insulin-like growth factor" Clin Endocrinol. (1978) 35:47-54.
Hintz et al., "Plasma somatomedin and growth hormone values in children with protein-calorie malnutrition" J. Pediatr. (1978) 92:153-156.
Dahn et al., "Insulin-like growth factor I production is inhibited in human sepsis" Arch. Surg. (1988) 123:1409-1414.
Miell et al., "Administration of human recombinant insulin-like growth factor-I to patients following major gastrointestinal surgery", Clin. Endocrinol. (1992) 37:542-551.
Cioffi et al., "Insulin-like growth factor-1 lowers protein oxidation in patients with thermal injury" Ann. Surg. (1994) 220:310-319.
Lieberman et al., "Anabolic effects of recombinant insulin-like growth factor-I in cachectic patients with acquired immunodeficiency syndrome" J. Clin. Endocrinol. Metabol. (1994) 78:404-410.
The Merck Manual of Diagnosis and Therapy, (1992) 16th ed., Berkow, R., ed., Merck Research Laboratories, Rahway, NJ. The title page and table of contents are included herewith.
Malozowski et al., "Risks and benefits of insulin-like growth factor" Ann. Int. Med. (1994) 121:549.
"Current Emergency Diagnosis and Treatment", (1992) 4 ed., Saunders et al., eds. Lange Medical Publications. The title page and table of contents are included herewith.
Jabri et al., "Adverse effects of recombi

Affiliated with

Also associated with

Rating

High dose IGF-1 therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with High dose IGF-1 therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and High dose IGF-1 therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1804582